By Alessandro Parodi Dec 12 (Reuters) - Global EV sales grew in November at the slowest rate since February 2024 as China ...

GXC trades at a modest sub-14x P/E, with large-cap, consumer discretionary, and communication services exposures dominating ...

The Federal Trade Commission (FTC) has declined to comment on its possible probe into AllTrack and Pro Music Rights (PMR).

Most of us think about health as something that pays off in our later years: fewer diseases and better aging. But a recent ...

MEG Energy’s narrative has shifted again, with the stock’s fair value held at CA$30.00 per share even as Street opinions diverge around the Cenovus deal. With revenue growth assumptions steady near 10 ...

The latest jump in Rhythm Pharmaceuticals (RYTM) shares is tied directly to encouraging preliminary Phase 2 data for setmelanotide in Prader Willi syndrome, where patients showed reductions in both ...

From Sony's acquisition of Hipgnosis Songs Group to the majors' licenses with Suno and Udio, here are the stories that ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

As existing resources are continually stretched thinner and thinner, experts and dialysis providers say it is crucial for ...

One mom shares her story of being one of many Americans who have traveled for fertility treatment.

I started on Mounjaro on the smallest dose of 2.5mg, and the effect was immediate - I completely lost interest in food. I ...

Explore how the future of obesity drugs starts in preclinical discovery, addressing global challenges and advancing treatment options.